Umecrine Cognition resumes patient inclusion in its clinical Phase I/IIa study of golexanolone in primary biliary cholangitis
STOCKHOLM – May 26, 2025. Umecrine Cognition today announces that the company has informed its clinical partners and study center investigators that they may resume the inclusion of eligible…